These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

329 related items for PubMed ID: 27750459

  • 1. Riociguat for the treatment of pulmonary hypertension: a safety evaluation.
    Binder C, Zotter-Tufaro C, Bonderman D.
    Expert Opin Drug Saf; 2016 Dec; 15(12):1671-1677. PubMed ID: 27750459
    [Abstract] [Full Text] [Related]

  • 2. Riociguat: a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension.
    Lian TY, Jiang X, Jing ZC.
    Drug Des Devel Ther; 2017 Dec; 11():1195-1207. PubMed ID: 28458514
    [Abstract] [Full Text] [Related]

  • 3. Riociguat: a novel new drug for treatment of pulmonary hypertension.
    Makowski CT, Rissmiller RW, Bullington WM.
    Pharmacotherapy; 2015 May; 35(5):502-19. PubMed ID: 26011143
    [Abstract] [Full Text] [Related]

  • 4. Riociguat for the treatment of pulmonary hypertension.
    Meis T, Behr J.
    Expert Opin Pharmacother; 2014 Nov; 15(16):2419-27. PubMed ID: 25260791
    [Abstract] [Full Text] [Related]

  • 5. Riociguat for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
    Bishop BM.
    Am J Health Syst Pharm; 2014 Nov 01; 71(21):1839-44. PubMed ID: 25320133
    [Abstract] [Full Text] [Related]

  • 6. Riociguat: a review of its use in patients with chronic thromboembolic pulmonary hypertension or pulmonary arterial hypertension.
    Garnock-Jones KP.
    Drugs; 2014 Nov 01; 74(17):2065-78. PubMed ID: 25352393
    [Abstract] [Full Text] [Related]

  • 7. Riociguat for the treatment of pulmonary hypertension.
    Schermuly RT, Janssen W, Weissmann N, Stasch JP, Grimminger F, Ghofrani HA.
    Expert Opin Investig Drugs; 2011 Apr 01; 20(4):567-76. PubMed ID: 21391889
    [Abstract] [Full Text] [Related]

  • 8. Riociguat, an oral soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension.
    Belik J.
    Curr Opin Investig Drugs; 2009 Sep 01; 10(9):971-9. PubMed ID: 19705340
    [Abstract] [Full Text] [Related]

  • 9. Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry.
    Ghofrani HA, Gomez Sanchez MA, Humbert M, Pittrow D, Simonneau G, Gall H, Grünig E, Klose H, Halank M, Langleben D, Snijder RJ, Escribano Subias P, Mielniczuk LM, Lange TJ, Vachiéry JL, Wirtz H, Helmersen DS, Tsangaris I, Barberá JA, Pepke-Zaba J, Boonstra A, Rosenkranz S, Ulrich S, Steringer-Mascherbauer R, Delcroix M, Jansa P, Šimková I, Giannakoulas G, Klotsche J, Williams E, Meier C, Hoeper MM, NEW COLLABORATORS LIST.
    Respir Med; 2021 Mar 01; 178():106220. PubMed ID: 33540340
    [Abstract] [Full Text] [Related]

  • 10. Riociguat for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Results from a phase II long-term extension study.
    Halank M, Hoeper MM, Ghofrani HA, Meyer FJ, Stähler G, Behr J, Ewert R, Fletcher M, Colorado P, Nikkho S, Grimminger F.
    Respir Med; 2017 Jul 01; 128():50-56. PubMed ID: 28610669
    [Abstract] [Full Text] [Related]

  • 11. The safety and effectiveness of riociguat to treat chronic thromboembolic pulmonary hypertension.
    DeSouza SA, Preston IR.
    Expert Rev Cardiovasc Ther; 2015 May 01; 13(5):467-76. PubMed ID: 25797801
    [Abstract] [Full Text] [Related]

  • 12. Riociguat (Adempas). Chronic thromboembolic pulmonary hypertension with markedly restricted physical activity.
    Prescrire Int; 2015 Nov 01; 24(165):265-6. PubMed ID: 26688897
    [Abstract] [Full Text] [Related]

  • 13. Overview of Riociguat and Its Role in the Treatment of Pulmonary Hypertension.
    Kenny M, Clarke MM, Pogue KT.
    J Pharm Pract; 2022 Jun 01; 35(3):437-444. PubMed ID: 33084500
    [Abstract] [Full Text] [Related]

  • 14. Riociguat for the management of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
    Larche NE, Mousa SA.
    Drugs Today (Barc); 2013 Dec 01; 49(12):761-8. PubMed ID: 24524094
    [Abstract] [Full Text] [Related]

  • 15. Soluble guanylate cyclase stimulators in pulmonary hypertension.
    Stasch JP, Evgenov OV.
    Handb Exp Pharmacol; 2013 Dec 01; 218():279-313. PubMed ID: 24092345
    [Abstract] [Full Text] [Related]

  • 16. Riociguat: a novel therapeutic option for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
    Mielniczuk LM, Swiston JR, Mehta S.
    Can J Cardiol; 2014 Oct 01; 30(10):1233-40. PubMed ID: 25154043
    [Abstract] [Full Text] [Related]

  • 17. Soluble guanylate cyclase stimulator riociguat and phosphodiesterase 5 inhibitor sildenafil ameliorate pulmonary hypertension due to left heart disease in mice.
    Pradhan K, Sydykov A, Tian X, Mamazhakypov A, Neupane B, Luitel H, Weissmann N, Seeger W, Grimminger F, Kretschmer A, Stasch JP, Ghofrani HA, Schermuly RT.
    Int J Cardiol; 2016 Aug 01; 216():85-91. PubMed ID: 27140341
    [Abstract] [Full Text] [Related]

  • 18. Riociguat: first global approval.
    Conole D, Scott LJ.
    Drugs; 2013 Nov 01; 73(17):1967-75. PubMed ID: 24218053
    [Abstract] [Full Text] [Related]

  • 19. Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access study.
    McLaughlin VV, Jansa P, Nielsen-Kudsk JE, Halank M, Simonneau G, Grünig E, Ulrich S, Rosenkranz S, Gómez Sánchez MA, Pulido T, Pepke-Zaba J, Barberá JA, Hoeper MM, Vachiéry JL, Lang I, Carvalho F, Meier C, Mueller K, Nikkho S, D'Armini AM.
    BMC Pulm Med; 2017 Dec 28; 17(1):216. PubMed ID: 29282032
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.